| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SYNJ2BP |
| Uniprot No | P57105 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-145aa |
| 氨基酸序列 | MNGRVDYLVTEEEINLTRGPSGLGFNIVGGTDQQYVSNDSGIYVSRIKENGAAALDGRLQ EGDKILSVNGQDLKNLLHQDAVDLFRNAGYAVSLRVQHRLQVQNGPIGHRGEGDPSGIPI FMVLVPVFALTMVAAWAFMRYRQQL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SYNJ2BP重组蛋白的3篇参考文献的简要列举(注：以下文献信息为示例性概括，具体内容请以实际文献为准)：
---
1. **文献名称**: "SYNJ2BP regulates mitochondrial dynamics and metabolic reprogramming in cancer cells"
**作者**: Kim S, et al.
**摘要**: 该研究利用重组SYNJ2BP蛋白，揭示了其通过调控线粒体分裂蛋白DRP1的活性，影响癌细胞代谢重编程和化疗耐药性的分子机制。
2. **文献名称**: "Recombinant SYNJ2BP inhibits viral replication by targeting MAVS-IRF3 signaling pathway"
**作者**: Zhang R, et al.
**摘要**: 研究发现重组SYNJ2BP蛋白通过与线粒体抗病毒信号蛋白MAVS相互作用，增强IRF3的激活，从而抑制RNA病毒复制，为抗病毒治疗提供新靶点。
3. **文献名称**: "Structural and functional analysis of the PDZ domain in SYNJ2BP recombinant protein"
**作者**: Gupta P, et al.
**摘要**: 通过解析重组SYNJ2BP蛋白的PDZ结构域晶体结构，结合突变分析，阐明其特异性识别C末端疏水性氨基酸的分子基础，并验证其在细胞极性建立中的功能。
---
如需查找真实文献，建议在PubMed、Google Scholar等平台以“SYNJ2BP recombinant protein”“SYNJ2BP function”等关键词检索。
Synj2bp (Synaptojanin-2-binding protein), also known as mitochondrial ribosome receptor BA42A5.2. is a protein involved in diverse cellular processes, including mitochondrial dynamics, cell adhesion, and apoptosis. It interacts with Synaptojanin-2. a phosphoinositide phosphatase, to regulate endocytic trafficking and signaling pathways. Structurally, SYNJ2BP contains a C-terminal PDZ domain that mediates protein-protein interactions and an N-terminal mitochondrial targeting sequence, enabling dual localization to mitochondria and the endoplasmic reticulum (ER). This dual localization suggests roles in ER-mitochondria communication, influencing calcium signaling and metabolic homeostasis.
Recombinant SYNJ2BP is engineered using expression systems like *E. coli* or mammalian cells to produce high-purity protein for functional studies. Researchers utilize it to investigate its binding partners, structural motifs, and regulatory mechanisms in diseases such as cancer and neurodegenerative disorders. Studies highlight its involvement in mitochondrial fragmentation and apoptosis via interactions with Bcl-2 family proteins, as well as its role in cell migration through integrin-mediated pathways. Recombinant SYNJ2BP also serves as a tool to explore its potential as a therapeutic target, particularly in cancers with dysregulated mitochondrial apoptosis or metastasis. Current research focuses on deciphering its precise molecular functions in membrane trafficking, organelle crosstalk, and disease pathology, aiming to uncover novel biomarkers or intervention strategies.
×
